Evidence map›Paper›PMID 33477667›Full record

ArticlePharmaceutics2021

Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases.

Raul Diaz-Salmeron, Balthazar Toussaint, Nicolas Huang, Etienne Bourgeois Ducournau, Gabriel Alviset, Sophie Goulay Dufaÿ, Hervé Hillaireau, Amélie Dufaÿ Wojcicki, Vincent Boudy

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Unlocking Potential ofGels (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Oral Gel Formulation ofPharmaceutics · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Hydrogels in Oral Disease Management: A Review of Innovations in Drug Delivery and Tissue Regeneration.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. International journal of molecular sciences · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Stimulus-Responsive Hydrogels as Drug Delivery Systems for Inflammation Targeted Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  20. Development and Evaluation ofTurkish journal of pharmaceutical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Raul Diaz-SalmeronDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.
Balthazar ToussaintDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.ORCID 0000-0001-7466-9442
Nicolas HuangInstitut Galien Paris Saclay, Université Paris-Saclay, CNRS, 92296 Châtenay-Malabry, France.ORCID 0000-0003-2750-3778
Etienne Bourgeois DucournauDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.
Gabriel AlvisetDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.ORCID 0000-0001-9677-2440
Sophie Goulay DufaÿDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.
Hervé HillaireauInstitut Galien Paris Saclay, Université Paris-Saclay, CNRS, 92296 Châtenay-Malabry, France.
Amélie Dufaÿ WojcickiDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.ORCID 0000-0002-3813-7120
Vincent BoudyDépartement de Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), 75005 Paris, France.ORCID 0000-0002-9811-1520
Générale de Santé · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FRUnité de Technologies Chimiques et Biologiques pour la Santé · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral lichen planus (OLP) is an ongoing and chronic inflammatory disease affecting the mucous membrane of the oral cavity. Currently, the treatment of choice consists in the direct application into the buccal cavity of semisolid formulations containing a corticosteroid molecule to decrease inflammatory signs and symptoms. However, this administration route has shown various disadvantages limiting its clinical use and efficacy. Indeed, the frequency of application and the incorrect use of the preparation may lead to a poor efficacy and limit the treatment compliance. Furthermore, the saliva clearance and the mechanical stress present in the buccal cavity also involve a decrease in the mucosal exposure to the drug. In this context, the design of a new pharmaceutical formulation, containing a steroidal anti-inflammatory, mucoadhesive, sprayable and exhibiting a sustained and controlled release seems to be suitable to overcome the main limitations of the existing pharmaceutical dosage forms. The present work reports the formulation, optimization and evaluation of the mucoadhesive and release properties of a poloxamer 407 thermosensitive hydrogel containing a poorly water-soluble corticosteroid, dexamethasone acetate (DMA), threaded into hydroxypropyl-beta-cyclodextrin (HP-β-CD) molecules. Firstly, physicochemical properties were assessed to ensure suitable complexation of DMA into HP-β-CD cavities. Then, rheological properties, in the presence and absence of various mucoadhesive agents, were determined and optimized. The hydration ratio (0.218-0.191), the poloxamer 407 (15-17 wt%) percentage and liquid-cyclodextrin state were optimized as a function of the gelation transition temperature, viscoelastic behavior and dynamic flow viscosity. Deformation and resistance properties were evaluated in the presence of various mucoadhesive compounds, being the sodium alginate and xanthan gum the most suitable to improve adhesion and mucoadhesion properties. Xanthan gum was shown as the best agent prolonging the hydrogel retention time up to 45 min. Furthermore, xanthan gum has been found as a relevant polymer matrix controlling drug release by diffusion and swelling processes in order to achieve therapeutic concentration for prolonged periods of time.

Indexed as

controlled-drug releasecyclodextrinsmucoadhesionpoloxamerspolysaccharides

Identifiers

PMID33477667
PMCPMC7831945
OpenAlexW3124322601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.